Latest Articles

Publication Date
All News Scientific
Merck’s endometrial cancer drug meets trial goals - Investing.com

Merck’s endometrial cancer drug meets trial goals Investing.com

Published: May 18, 2026, 11:15 a.m.
Read Full Article
Merck’s Sac-TMT met primary endpoints in endometrial cancer trial - TipRanks

Merck’s Sac-TMT met primary endpoints in endometrial cancer trial TipRanks

Published: May 18, 2026, 11:10 a.m.
Read Full Article
Merck’s endometrial cancer drug meets trial goals By Investing.com - Investing.com Canada

Merck’s endometrial cancer drug meets trial goals By Investing.com Investing.com Canada

Published: May 18, 2026, 11:01 a.m.
Read Full Article
Merck's endometrial cancer drug meets late-stage trial goals - Reuters

Merck's endometrial cancer drug meets late-stage trial goals Reuters

Published: May 18, 2026, 10:51 a.m.
Read Full Article
Merck's endometrial cancer drug meets late-stage trial goals - Yahoo Finance

Merck's endometrial cancer drug meets late-stage trial goals Yahoo Finance

Published: May 18, 2026, 10:51 a.m.
Read Full Article
Merck endometrial cancer drug meets survival goals in phase 3 trial - StreetInsider

Merck endometrial cancer drug meets survival goals in phase 3 trial StreetInsider

Published: May 18, 2026, 10:47 a.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Read Full Article
GSK preps lawsuit against US firm AnaptysBioover endometrial cancer drug - MSN

GSK preps lawsuit against US firm AnaptysBioover endometrial cancer drug MSN

Published: May 17, 2026, 7:18 p.m.
Read Full Article
The Four Types of Therapy for Second-Line Endometrial Cancer - CancerNetwork

The Four Types of Therapy for Second-Line Endometrial Cancer CancerNetwork

Published: May 16, 2026, 2:04 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!